-
Offering Date
-
January 01, 0001
Company Description
EnClear Therapies is an early-stage company that is combining bio & medtech expertise to develop systems capable of halting the progression of neurodegenerative diseases by removing toxic proteins that are known to aggregate in the body and drive disease progression.
Key Deal Facts
Potential for ground-breaking ALS treatment where no alternative patient treatments currently exist
On track for FDA approval within 2 years and virtual-monopoly of initial $2B market, with platform potential to expand to additional disease areas (e.g. Alzheimer's, Parkinson's) and partner with drug and diagnostic companies
Initial device development already funded by Amgen Ventures (Big Pharma; potential partner)
World-class management and advisor team (Harvard Med, MIT, Medtronic, J&J, Boston Scientific) with extensive experience in medical device development, neurodegenerative disease pathology, neurosurgery, and premier expertise in assay development (EnClear core technology)
The company's past round included participation from Thiel Capital, continued funding/strategic support from Amgen and angel participation from Bain Consulting's Head of U.S. Healthcare, Medtronic's Head of Program Mgmt/Strategy, and a Harvard Medical Professor in Neurosurgical Critical Care
Since EnClear’s Seed round:
EnClear added key hires with extensive industry experience from Medtronic, Boston Scientific, and Deloitte
The team hit key milestones spanning system design, preclinical testing, and method development
With its track record of execution and positive results, EnClear recently closed its Series A round, which included notable participation from new VCs & strategics as well as strong continued support from existing investors
Management Team / Advisory Board Bios
ANTHONY DEPASQUA
President & CEO
20 years Med Tech Experience: Medtronic, Salient Surgical, HydroCision, Harvest Technologies
KEVIN KALISH
VP of R&D
15 yrs experience in medical device industry including Medtronic and Boston Scientific
LAURA PAULSEN
Director of BD and Clinical
10 yrs experience in medical device industry at Medtronic and Deloitte and biomedical engineer
BILL SIOPES
Director of R&D
15 yrs experience in medical device industry at Medtronic, Millipore, and NP Medical
DR. KEVIN EGGAN
Scientific Advisor
Professor, Department of Stem Cell and Regenerative Biology, Harvard University; Director, Stem Cell Biology, The Broad Institute
KASPER ROET
Head of Discovery
PhD in Neuroscience, CEO of QurAlis – ALS therapeutics company
DR. WILLIAM GORMLEY
Chief Medical Officer
Director, Neurosurgical Critical Care, Brigham and Women's Hospital; Associate Professor, Harvard Medical School
JONATHAN FLEMING
Board Chairman
Lecturer, MIT Sloan, Oxford Bioscience Partners
